Literature DB >> 26379973

Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population.

Hui-Ning Liu1, Jian-Ling Su2, Shao-Hui Zhou1, Li-Jun Liu1, Peng Qie1.   

Abstract

BACKGROUND: CTLA-4 is a potent immunoregulatory molecule and plays a pivotal role in the negative regulation of T-cell proliferation and activation. Previously, the association between CTLA-4 +49A>G polymorphism and the risk of NSCLC has been investigated in several studies, however, their results were inconsistent. Therefore, we aimed to investigated the association between CTLA-4 +49A>G polymorphism and the risk of NSCLC in a Chinese population.
METHODS: We recruited 231 NSCLC patients and 250 healthy controls in the present case-control study. PCR-RFLP was used to analyze the polymorphism of CTLA-4. The chi-squared test was used to examine differences between NSCLC patients and controls. The odds ratio (OR) and its 95% confidence interval (95% CI) were obtained by logistic regression methodology to determine correlations between the CTLA-4 polymorphism and the incidence of NSCLC.
RESULTS: When the AA genotype was used as the reference group, the GG genotype was significantly associated with increased risk for NSCLC (OR=2.181, 95% CI: 1.244-5.198; P=0.007), however, the AG genotype was not significantly associated with increased risk for NSCLC (OR=2.018, 95% CI: 0.826-3.881; P=0.099). Under the dominant model of inheritance, the AG+GG genotype was significantly associated with increased risk for NSCLC (OR=3.271, 95% CI: 1.827-4.559; P=0.015). In addition, the G allele had a 2.754-fold higher risk of NSCLC in comparison with the A allele (OR=2.754, 95% CI: 1.365-6.891, P=0.005).
CONCLUSIONS: Our data provided evidence that the CTLA-4 +49A>G polymorphism is associated with increased risk of NSLCL in Chinese population.

Entities:  

Keywords:  CTLA-4; NSCLC; polymorphism; risk

Year:  2015        PMID: 26379973      PMCID: PMC4565356     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

Review 1.  The DNA damage response: putting checkpoints in perspective.

Authors:  B B Zhou; S J Elledge
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

2.  CTLA-4 regulates cell cycle progression during a primary immune response.

Authors:  Rebecca J Greenwald; Mariette A Oosterwegel; Diane van der Woude; Anup Kubal; Didier A Mandelbrot; Vassiliki A Boussiotis; Arlene H Sharpe
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

3.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

4.  ctla-4 gene variations may influence cervical cancer susceptibility.

Authors:  Shahrzad Rahimifar; Nasrollah Erfani; Zahra Sarraf; Abbas Ghaderi
Journal:  Gynecol Oncol       Date:  2010-07-07       Impact factor: 5.482

5.  CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease.

Authors:  T Kouki; Y Sawai; C A Gardine; M E Fisfalen; M L Alegre; L J DeGroot
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma.

Authors:  Maria Monne; Giovanna Piras; Angelo Palmas; Luigi Arru; Marco Murineddu; Giancarlo Latte; Annalisa Noli; Attilio Gabbas
Journal:  Am J Hematol       Date:  2004-05       Impact factor: 10.047

7.  MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients.

Authors:  Xia Pu; Jack A Roth; Michelle A T Hildebrandt; Yuanqing Ye; Hua Wei; John D Minna; Scott M Lippman; Xifeng Wu
Journal:  Cancer Res       Date:  2013-02-01       Impact factor: 12.701

Review 8.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

9.  Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer.

Authors:  Tong Sun; Yifeng Zhou; Ming Yang; Zhibin Hu; Wen Tan; Xiaohong Han; Yuankai Shi; Jiarui Yao; Yongli Guo; Dianke Yu; Tian Tian; Xiaoyi Zhou; Hongbing Shen; Dongxin Lin
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer.

Authors:  Adam Antczak; Dorota Pastuszak-Lewandoska; Paweł Górski; Daria Domańska; Monika Migdalska-Sęk; Karolina Czarnecka; Ewa Nawrot; Jacek Kordiak; Ewa Brzeziańska
Journal:  Biomed Res Int       Date:  2013-07-09       Impact factor: 3.411

View more
  1 in total

1.  Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.

Authors:  Hongyuan Wan; Hangsheng Zhou; Yanyan Feng; Yongquan Chen; Lijie Zhu; Yuanyuan Mi
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.